Aura Biosciences Reports Fourth Quarter and Full Year 2023 Financial Results and Business Highlights
Aura Biosciences to Participate in Upcoming Investor Conferences
Aura Biosciences Announces First Patient Dosed in Global Phase 3 CoMpass Trial Evaluating the Safety and Efficacy of Belzupacap Sarotalocan (Bel-sar) for First-Line Treatment of Early-Stage Choroidal Melanoma
Aura Biosciences Reports Third Quarter 2023 Financial Results and Provides Clinical Development and Operational Highlights
Aura Biosciences to Participate in Upcoming Investor Conferences
Aura Biosciences Receives FDA Agreement SPA for CoMpass Phase 3 Trial of Bel-sar
Aura Biosciences Announces Pricing of Public Offering of Common Stock
Aura to Present Phase 2 Data Evaluating Suprachoroidal Administration of Bel-sar
Aura Biosciences Strengthens and Expands Leadership Team with Key Appointments
Aura Biosciences Reports Second Quarter 2023 Financial Results and Provides Clinical Development and Operational Highlights